scholarly journals Evaluation of the Diagnostic Value of Non-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort

2021 ◽  
Vol 12 ◽  
Author(s):  
Chaojun Hu ◽  
Siting Li ◽  
Zhijuan Xie ◽  
Hanxiao You ◽  
Hui Jiang ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Medical Practice ◽  
Predictive Power ◽  
Diagnostic Value ◽  
Annexin A5 ◽  
Healthy Controls ◽  
Glycoprotein I ◽  
Number Of Patients ◽  
Chinese Cohort ◽  
New Biomarkers

ObjectiveAlthough specific anti-phospholipid antibodies (aPLs) have been used in the diagnosis of the antiphospholipid syndrome (APS) for years, new biomarkers are required to increase its diagnostic and risk-predictive power. This study aimed to explore the value of several non-criteria aPLs in a Chinese cohort.MethodsA total of 312 subjects, namely, 100 patients diagnosed with primary APS, 51 with APS secondary to SLE, 71 with SLE, and 90 healthy controls, were recruited. Serum anticardiolipin (aCL) IgG/IgM/IgA, anti-β2-glycoprotein I (aβ2GPI) IgG/IgM/IgA, anti-phosphatidylserine/prothrombin antibodies (aPS/PT) IgG/IgM, and anti-annexin A5 antibodies (aAnxV) IgG/IgM were tested using ELISA kits.ResultsOf the total number of patients, 30.46% and 6.62% with APS were positive for aCL or aβ2GPI IgA, respectively, while 39.07% and 24.50% were positive for aAnxV or aPS/PT for at least one antibody (IgG or IgM). The addition test of aCL IgA and aAnxV IgM assists in identifying seronegative APS patients, and IgG aPS/PT was linked to stroke.ConclusionDetection of aCL IgA, aβ2GPI IgA, aAnxV IgG/M, and aPS/PT IgG/M as a biomarker provides additive value in APS diagnosis and would help in risk prediction for APS patients in medical practice.

scholarly journals Evaluation of the Diagnostic Value of Extra-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort

2021 ◽  
Author(s):  
Chaojun Hu ◽  
Siting Li ◽  
Zhijuan Xie ◽  
Hanxiao You ◽  
Hui Jiang ◽  
...  
Keyword(s):  
Risk Prediction ◽  
Antiphospholipid Syndrome ◽  
Medical Practice ◽  
Predictive Power ◽  
Diagnostic Value ◽  
Annexin A5 ◽  
Glycoprotein I ◽  
Chinese Cohort ◽  
New Biomarkers

Objective： Although specific anti-phospholipids antibodies (aPLs) have been used in the diagnosis of the antiphospholipid syndrome (APS) for years, new biomarkers are required to increase its diagnostic as well as risk-predictive power. This study aimed to explore the value of several extra-criteria aPLs in a Chinese cohort. Methods： A total of 312 patients including 100 patients diagnosed with primary APS, 51 with APS secondary to SLE, 71 with SLE, and 90 health controls were recruited. Serum anticardiolipin (aCL) IgG/IgM/IgA, anti-β2-glycoprotein I (aβ2GPI) IgG/IgM/IgA, anti-phosphatidylserine/prothrombin antibodies (aPS/PT) IgG/IgM, anti-annexin A5 antibodies (aAnxV) IgG/IgM were tested using ELISA kits. Results： Totally 30.46% and 6.62% of patients with APS were positive for aCL or aβ2GPI IgA respectively, while 39.07% and 24.50% were positive for aAnxV or aPS/PT for at least one antibodies (IgG or IgM). The addition test of aCL IgA and aAnxV IgM assist in identifying seronegative APS patients, and IgG aANxV was linked with stroke. Conclusion： Detection of aCL IgA, aβ2GPI IgA, aAnxV IgG/M, and aPS/PT IgG/M as biomarker provide additive value in APS diagnosis, and would help in risk prediction for APS patients in medical practice.

scholarly journals Anticardiolipin Antibodies in Patients with Chronic Hepatitis C Virus Infection: Characterization in Relation to Antiphospholipid Syndrome

2000 ◽  
Vol 7 (2) ◽  
pp. 241-244 ◽  
Author(s):  
Josep Ordi-Ros ◽  
Julieta Villarreal ◽  
Francesc Monegal ◽  
Silvia Sauleda ◽  
Ignacio Esteban ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiphospholipid Syndrome ◽  
Clinical Manifestations ◽  
Cross Reactivity ◽  
Healthy Controls ◽  
Glycoprotein I ◽  
Chronic Hepatitis C Virus

ABSTRACT The antiphospholipid syndrome (APS) is usually defined by the association of clinical manifestations that comprise venous and/or arterial thrombosis, recurrent fetal losses, and thrombocytopenia, along with the presence of anticardiolipin (aCL) antibodies and/or lupus anticoagulant. Various infectious diseases can induce aCL; however, these antibodies are not usually associated with thrombotic events, as happens with autoimmune diseases, in which these antibodies need the presence of β2-glycoprotein I. Levels of immunoglobulin G (IgG) and IgM aCL antibodies were determined by enzyme-linked immunosorbent assay for 243 patients with chronic hepatitis C virus (HCV) infection and 100 healthy controls. Clinical events of APS, the level of β2-glycoprotein dependence of aCL, the presence of cryoglobulins and other autoantibodies, and cross-reactivity between purified aCL and HCV were evaluated. Positive results for aCL antibodies were found more frequently (3.3%) for the patients with HCV infection than for healthy controls (0%). All positive aCL antibodies were β2-glycoprotein I independent. No significant association was found between aCL antibodies and clinical manifestations of APS, neither was one found between the presence of other autoantibodies or cryoglobulins and that of aCL. Finally, no cross-reactivity between aCL antibodies and HCV antigens was observed. As previously reported, aCL antibodies seem to be an epiphenomenon, and they do not have clinical or laboratory significance in HCV patients.

Variability in Exposure of Epitope G40-R43 of Domain I in Commercial Anti-β2-Glycoprotein I IgG Elisas Influences the Diagnosis of the Antiphospholipid Syndrome

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 632-632
Author(s):  
Leonie Pelkmans ◽  
Hilde Kelchtermans ◽  
Marisa Ninivaggi ◽  
Theo Lindhout ◽  
Philip G de Groot ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Conflicts Of Interest ◽  
High Variability ◽  
Diagnostic Assays ◽  
Glycoprotein I ◽  
Open Conformation ◽  
Lower Reactivity ◽  
Number Of Patients ◽  
Cryptic Epitope ◽  
Domain I

Abstract Abstract 632 Introduction. Diagnosis of the antiphospholipid syndrome (APS) depends on the detection of autoantibodies against phospholipid-bound β2-glycoprotein I (β2GPI), the most prominent antigen in APS. One of the main problems faced is the high variability observed between different commercially available anti-β2GPI assays. Anti-β2GPI antibodies constitute a heterogeneous population, but predominantly antibodies reacting to a cryptic epitope Glycine40-Arginine43 (G40-R43) in domain I of β2GPI are associated with a strong risk to develop thrombosis. b2GPI is present in blood in a native conformation (either circular or S-shaped). After interaction with anionic surfaces it opens up (J-shaped conformation), resulting in exposure of the epitope G40-R43 in domain I. It is therefore important that in diagnostic assays b2GPI is presented in the open conformation enabling antibodies to react with the G40-R43 epitope. We hypothesize that the high variability between different commercial anti-b2GPI ELISA assays arise from variation in exposure of the G40-R43 epitope of b2GPI. Methods. Two patient-derived monoclonal antibodies P2-6 and P1-117 were tested for their reactivity towards β2GPI in different conformations. Using both antibodies, we compared exposure of epitope G40-R43 on β2GPI in five different commercial anti-β2GPI IgG assays. 10 patient samples selected for their low to high positivity towards epitope G40-R43, were tested in two anti-β2GPI IgG assays. Results. Using neutral versus anionic ELISA plates, we have shown that antibody P1-117 specifically reacts with epitope G40-R43, exposed only in the open conformation, while antibody P2-6 recognizes β2GPI irrespective of its conformation (Fig. 1). In one of the tested anti-β2GPI assays, both antibodies showed equal reactivity towards β2GPI, indicating that all the coated β2GPI exposes epitope G40-R43. In this assay, all ten anti-domain I positive patients tested positive. In other assays P1-117 displayed lower reactivity towards β2GPI than P2-6, demonstrating a reduced exposure of G40-R43. Only 3 out of the 10 patients tested positive in such assay, illustrating that a significant number of patients can be falsely assigned negative in assays characterized by a reduced exposure of epitope G40-R43. Conclusions. The exposure of epitope G40-R43 on β2GPI is highly variable in commercial anti-β2GPI assays, and influences the diagnosis of APS. Our results have major implications for the diagnosis of APS, as it provides suitable controls to ensure sufficient exposure of the G40-R43 epitope or suggests the development of alternative assays coating only domain I of β2GPI. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Diagnostic value of anti-annexin A5 antibodies in seropositive versus seronegative antiphospholipid syndrome patients

2018 ◽  
Vol 40 (2) ◽  
pp. 111-116
Author(s):  
Gihan Omar ◽  
Faten Ismail Mohamed ◽  
Hanaa Ahmad Sadek ◽  
Al Shimaa Mamdouh
Keyword(s):  
Antiphospholipid Syndrome ◽  
Diagnostic Value ◽  
Annexin A5

The Clinical Relevance of Noncriteria Antiphospholipid Antibodies

2017 ◽  
Vol 44 (05) ◽  
pp. 453-457 ◽  
Author(s):  
Giovanni Sanna ◽  
Maria Bertolaccini
Keyword(s):  
Antiphospholipid Syndrome ◽  
Clinical Relevance ◽  
Antiphospholipid Antibodies ◽  
Lupus Anticoagulant ◽  
Clinical Utility ◽  
Diagnostic Value ◽  
Anticardiolipin Antibodies ◽  
Coagulation Cascade ◽  
Glycoprotein I

AbstractWhile lupus anticoagulant (LA), anticardiolipin antibodies (aCL), anti-β2 glycoprotein I (anti-β2GPI) antibodies represent the best available and the most widely used tests in the investigation for antiphospholipid syndrome (APS), evidence gathered in recent years indicates that other antiphospholipid antibodies (aPL) specificities may also play a role in the syndrome. Several autoantibodies have been shown to be complexed with phospholipids other than cardiolipin, or to some domains of β2GPI, or else directed to other proteins of the coagulation cascade, and these have also been proposed to be of relevance to APS, and their diagnostic value and clinical utility are the focus of current research.

scholarly journals Antibodies against Glucan, Chitin, and Saccharomyces cerevisiae Mannan as New Biomarkers of Candida albicans Infection That Complement Tests Based on C. albicans Mannan

2008 ◽  
Vol 15 (12) ◽  
pp. 1868-1877 ◽  
Author(s):  
B. Sendid ◽  
N. Dotan ◽  
S. Nseir ◽  
C. Savaux ◽  
P. Vandewalle ◽  
...  
Keyword(s):  
Saccharomyces Cerevisiae ◽  
Candida Albicans ◽  
Time Course ◽  
Fungal Infections ◽  
Diagnostic Value ◽  
Antibody Detection ◽  
Healthy Controls ◽  
Candida Albicans Infection ◽  
New Biomarkers ◽  
Kinetics Of

ABSTRACT Antibodies against Saccharomyces cerevisiae mannan (ASCA) and antibodies against synthetic disaccharide fragments of glucans (ALCA) and chitin (ACCA) are biomarkers of Crohn's disease (CD). We previously showed that Candida albicans infection generates ASCA. Here, we explored ALCA and ACCA as possible biomarkers of invasive C. albicans infection (ICI). ASCA, ALCA, ACCA, and Candida mannan antigen and antibody detection tests were performed on 69 sera obtained sequentially from 18 patients with ICIs proven by blood culture, 59 sera from CD patients, 47 sera from hospitalized subjects colonized by Candida species (CZ), and 131 sera from healthy controls (HC). ASCA, ALCA, and ACCA levels in CD and ICI patients were significantly different from those in CZ and HC subjects (P < 0.0001). In ICI patients, these levels increased as infection developed. Using ASCA, ALCA, ACCA, and Platelia Candida tests, 100% of ICIs were detected, with the kinetics of the antibody response depending on the patient during the time course of infection. A large number of sera presented with more than three positive tests. This is the first evidence that the detection of antibodies against chitin and glucans has diagnostic value in fungal infections and that these tests can complement more specific tests. Future trials are necessary to assess the value of these tests in multiparametric analysis, as well as their pathophysiological relevance.

Antiprothrombin antibody: why do we need more assays?

Lupus ◽  
2010 ◽  
Vol 19 (4) ◽  
pp. 436-439 ◽  
Author(s):  
T. Atsumi ◽  
T. Koike
Keyword(s):  
Sensitivity And Specificity ◽  
Antiphospholipid Syndrome ◽  
Lupus Anticoagulant ◽  
Laboratory Tests ◽  
Diagnostic Value ◽  
Anticardiolipin Antibodies ◽  
Confirmatory Test ◽  
Enzyme Linked Immunosorbent Assay ◽  
Glycoprotein I

Anticardiolipin antibodies (aCL), anti-β2-glycoprotein I (β2GPI) antibodies and lupus anticoagulant (LA) are the only laboratory tests considered within the revised criteria for the classification of the antiphospholipid syndrome (APS). Recently, the significance to assay the antibodies against phosphatidylserine—prothrombin complex (aPS/PT) has been discussed, and these antibodies, rather than antibodies against prothrombin alone, are closely associated with APS and LA. The sensitivity and specificity of aPS/PT for the diagnosis of APS were assessed in a population of patients with a variety of autoimmune disorders. The aCL and aPS/PT have similar diagnostic value for APS, and most of APS patients with aPS/PT had positive LA. Therefore, aPS/PT should be further explored, not only for research purposes, but also as a candidate for one of the enzyme-linked immunosorbent assay (ELISA)-based confirmatory test for APS associated LA.

scholarly journals Non-criteria Antiphospholipid Antibodies: a narrative review

2020 ◽  
Vol 66 (11) ◽  
pp. 1595-1601
Author(s):  
Andreas Funke ◽  
Henrique Luiz Staub ◽  
Odirlei Andre Monticielo ◽  
Gustavo Guimarães Moreira Balbi ◽  
Adriana Danowski ◽  
...  
Keyword(s):  
Sensitivity And Specificity ◽  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Laboratory Diagnosis ◽  
Diagnostic Value ◽  
Classification Criteria ◽  
Narrative Review ◽  
Annexin A5 ◽  
Clinical Associations ◽  
Domain I

SUMMARY The 2006 Revised Sapporo Classification Criteria for Definite Antiphospholipid Syndrome included as laboratory criteria the tests for antiphospholipid antibodies whose accuracy was regarded as satisfactory according to the evidence available at that time. In practice, however, the sensitivity and specificity of these “criteria” of antiphospholipid antibodies are sometimes insufficient for identifying or ruling out antiphospholipid syndrome. It has been studied whether the accuracy of the laboratory diagnosis of the syndrome could be improved by testing for non-criteria antiphospholipid antibodies. In this work, we review evidence on the clinical associations and diagnostic value of the most commonly studied non-criteria antibodies, namely: antiphosphatidylethanolamine, anti-annexin A5, anti-prothrombin, anti-phosphatidylserine/prothrombin complex, IgA anticardiolipin, and IgG anti-domain I of the β2 glycoprotein antibodies.

Computer-Aided Diagnosis in Jaundice: Comparison of Knowledge-based and Probabilistic Approaches

1996 ◽  
Vol 35 (01) ◽  
pp. 41-51 ◽  
Author(s):  
F. Molino ◽  
D. Furia ◽  
F. Bar ◽  
S. Battista ◽  
N. Cappello ◽  
...  
Keyword(s):  
Clinical Presentation ◽  
Clinical Information ◽  
Diagnostic Value ◽  
Clinical Findings ◽  
Clinical Documentation ◽  
Data Set ◽  
Knowledge Based ◽  
Number Of Patients ◽  
Support Tools ◽  
Aided Diagnosis

AbstractThe study reported in this paper is aimed at evaluating the effectiveness of a knowledge-based expert system (ICTERUS) in diagnosing jaundiced patients, compared with a statistical system based on probabilistic concepts (TRIAL). The performances of both systems have been evaluated using the same set of data in the same number of patients. Both systems are spin-off products of the European project Euricterus, an EC-COMACBME Project designed to document the occurrence and diagnostic value of clinical findings in the clinical presentation of jaundice in Europe, and have been developed as decision-making tools for the identification of the cause of jaundice based only on clinical information and routine investigations. Two groups of jaundiced patients were studied, including 500 (retrospective sample) and 100 (prospective sample) subjects, respectively. All patients were independently submitted to both decision-support tools. The input of both systems was the data set agreed within the Euricterus Project. The performances of both systems were evaluated with respect to the reference diagnoses provided by experts on the basis of the full clinical documentation. Results indicate that both systems are clinically reliable, although the diagnostic prediction provided by the knowledge-based approach is slightly better.

Sign in / Sign up

Export Citation Format

Share Document